

Dated - 07.02.2024

BSE LIMITED

Corporate Relations Department
Phiroze Jeejeebhoy Towers
Dalal Street, Fort
Mumbai-400001
Scrip code: 543264

NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Listing Department
Exchange Plaza, 5th Floor, Plot no. C/1
G Block, Bandra Kurla Complex, Bandra (E)
Mumbai-400051
Scrip Code: NURECA

Subject: Outcome of Board Meeting under Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

This is to inform you that the Board of Directors of the Company at the Meeting held today i.e. February 7, 2024 (Wednesday) have approved the unaudited Standalone and Consolidated Financial Results of the Company for the third quarter and nine months ended December 31, 2023.

Copies of the unaudited Standalone and Consolidated Financial Results along with Limited Review Reports from the Company's Statutory Auditors are enclosed herewith.

The Board Meeting commenced at 4:00 PM and concluded at 5:10 PM.

This is for your kind information and records please.

Thanking You,

Yours Sincerely,
For **Nureca Limited**

(Chetna Anand)
Company Secretary & Compliance Officer

NURECA LIMITED							
Office Number 101, 1st Floor Udyog Bhavan Sonawala Lane, Goregaon (East), Mumbai - 400063, Maharashtra, India Tel: +91 -172-5292900, E-mail: cs@nureca.com, Website: www.nureca.com Corporate Identification Number: L24304MH2016PLC320868							
(Amount in INR million, unless otherwise stated)							
Statement of Unaudited Standalone Financial Results for the quarter and nine months ended 31 December 2023							
Sr. No.	Particulars	Quarter ended			Nine months ended		Year ended
		31 December 2023 (Unaudited)	30 September 2023 (Unaudited)	31 December 2022 (Unaudited)	31 December 2023 (Unaudited)	31 December 2022 (Unaudited)	31 March 2023 (Audited)
1	Revenue from operations	223.74	313.53	278.36	749.58	906.82	1,118.99
2	Other income	59.21	32.07	19.24	118.13	50.12	71.65
3	Total income (1+2)	282.95	345.60	297.60	867.71	956.94	1,190.64
4	Expenses						
	Purchase of stock-in-trade	104.53	164.92	112.83	503.73	372.06	470.82
	Changes in inventories of stock-in-trade	66.11	36.63	62.72	18.07	254.74	307.17
	Employee benefits expense	31.05	29.13	38.37	86.57	128.78	155.09
	Finance costs	1.01	0.80	1.03	2.89	3.31	4.31
	Depreciation and amortization expense	5.62	5.60	5.76	16.78	17.66	23.01
	Other expenses	66.33	72.46	76.84	204.94	267.00	339.81
	Total expenses	274.65	309.54	297.55	832.98	1,043.55	1,300.21
5	Profit/ (loss) before income tax (3-4)	8.30	36.06	0.05	34.73	(86.61)	(109.57)
6	Tax expense						
	- Current tax	11.72	2.26	-	13.98	-	0.41
	- Deferred tax (credit)/ charge	(4.20)	7.44	(0.23)	1.03	(20.38)	(25.76)
7	Profit/ (loss) after income tax (5-6)	0.78	26.36	0.28	19.72	(66.23)	(84.22)
8	Other comprehensive (expense)/ income						
A	(i) Item that will not be reclassified to profit or loss	(0.19)	(0.20)	0.48	(0.58)	1.44	(0.77)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.05	0.05	(0.12)	0.15	(0.36)	0.19
B	(i) Item that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other comprehensive (expense) for the period/ year (net of tax)	(0.14)	(0.15)	0.36	(0.43)	1.08	(0.58)
9	Total comprehensive income/ (expense) for the period/ year (7+8)	0.64	26.21	0.64	19.29	(65.15)	(84.80)
10	Earning/ (loss) per share of Rs. 10 each - Basic and diluted (in rupees) (not annualized)	0.08	2.64	0.03	1.97	(6.62)	(8.42)
11	Paid-up equity share capital (Face value of share - Rs.10 each)	100.00	100.00	100.00	100.00	100.00	100.00
12	Other equity						1,852.62
	See accompanying notes to the unaudited standalone financial results						



NURECA LIMITED

Correspondence Office : SCO 6-7-8, 1st Floor, Madhya Marg, Sector 9-D, Chandigarh 160009
Registered Office : 101 Office Number, Udyog Bhavan, 1st Floor, Sonawala Lane, Goregaon East,
Mumbai City Maharashtra - 400063


Phone No. +91-172-5292900 CIN L24304MH2016PLC320868

NURECA LIMITED

Office Number 101, 1st Floor Udyog Bhavan Sonawala Lane, Goregaon (East), Mumbai - 400063, Maharashtra, India
Tel: +91 -172-5292900, E-mail: cs@nureca.com, Website: www.nureca.com
Corporate Identification Number: L24304MH2016PLC320868

Notes to the unaudited standalone financial results:

- 1 The above unaudited standalone financial results for the quarter and nine months ended 31 December 2023 as reviewed by the Audit Committee, have been approved at the meeting of the Board of Directors held on 07 February 2024. The limited review report of the Statutory Auditors is being filed with the BSE Limited and National Stock Exchange of India Limited. For more details, visit the investor relation section of our website www.nureca.com and financials results at corporate section at www.bseindia.com and www.nseindia.com.
- 2 The business of the Company falls within single line of business i.e. business of home healthcare and wellness products.

 For and on behalf of Board of Directors of
Nureca Limited
Saurabh Goyal
(Managing Director)
DIN : 00136037

Place: Chandigarh
Date: 07.02.2024

NURECA LIMITED

Correspondence Office : SCO 6-7-8, 1st Floor, Madhya Marg, Sector 9-D, Chandigarh 160009
Registered Office : 101 Office Number, Udyog Bhavan, 1st Floor, Sonawala Lane, Goregaon East,
Mumbai City Maharashtra - 400063

Phone No. +91-172-5292900 CIN L24304MH2016PLC320868

Limited Review Report on unaudited standalone financial results of Nureca Limited for the quarter ended 31 December 2023 and year to date from 01 April 2023 to 31 Decemeber 2023 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended


To the Board of Directors of Nureca Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Nureca Limited (hereinafter referred to as "the Company") for the quarter ended 31 December 2023 and year to date results for the period from 01 April 2023 to 31 December 2023 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022



Ankush Goel

Partner

New Delhi

07 February 2024

Membership No.: 505121

UDIN:24505121BKGXCW2273

Registered Office:

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400063

NURECA LIMITED

Office Number 101, 1st Floor Udyog Bhavan Sonawala Lane, Goregaon (East), Mumbai - 400063, Maharashtra, India
Tel: +91 -172-5292900, E-mail: cs@nureca.com, Website: www.nureca.com
Corporate Identification Number: L24304MH2016PLC320868

(Amount in INR million, unless otherwise stated)

Statement of Unaudited Consolidated Financial Results for the quarter and nine months ended 31 December 2023

Sr. No.	Particulars	Quarter ended			Nine Months ended		Year ended
		31 December 2023 (Unaudited)	30 September 2023 (Unaudited)	31 December 2022 Refer Note 3	31 December 2023 (Unaudited)	31 December 2022 Refer Note 3	31 March 2023 (Audited)
1	Revenue from operations	223.74	313.53	277.88	749.58	900.97	1,113.23
2	Other income	59.01	31.99	18.96	117.73	49.57	71.05
3	Total income (1+2)	282.75	345.52	296.84	867.31	950.54	1,184.28
4	Expenses						
	Cost of material consumed	43.96	30.20	20.50	87.14	27.96	35.18
	Purchase of stock-in-trade	49.46	123.48	83.69	389.66	331.49	412.42
	Changes in inventories of stock-in-trade and finished goods	65.37	37.66	62.94	17.54	252.65	307.71
	Employee benefits expense	32.79	30.65	39.87	91.33	132.69	160.59
	Finance costs	1.10	0.84	1.09	3.10	3.46	4.50
	Depreciation and amortization expense	5.91	5.88	6.01	17.62	18.27	23.88
	Other expenses	74.71	77.69	80.04	221.64	271.71	347.42
	Total expenses	273.30	306.40	294.14	828.03	1,038.23	1,291.70
5	Profit/ (loss) before income tax (3-4)	9.45	39.12	2.70	39.28	(87.69)	(107.42)
6	Tax expense						
	- Current tax	12.32	2.94	0.20	15.52	0.20	1.16
	- Deferred tax (credit)/ charge	(4.52)	7.24	(0.51)	0.24	(20.69)	(26.08)
7	Profit/ (loss) after income tax (5-6)	1.65	28.94	3.01	23.52	(67.20)	(82.50)
8	Other comprehensive (expense)/ income						
A	(i) Item that will not be reclassified to profit or loss	(0.19)	(0.20)	0.48	(0.58)	1.44	(0.77)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.05	0.05	(0.12)	0.15	(0.36)	0.19
B	(i) Item that will be reclassified to profit or loss	(0.00)	0.06	(0.03)	(0.02)	(0.06)	(0.09)
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other comprehensive (expense)/ income for the period/ year (net of tax)	(0.14)	(0.09)	0.33	(0.45)	1.02	(0.67)
9	Total comprehensive income/ (expense) for the period/ year (7+8)	1.51	28.85	3.34	23.07	(66.18)	(83.17)
10	Earning/ (loss) per share of Rs. 10 each						
	- Basic and diluted (in rupees) (not annualized)	0.16	2.90	0.30	2.35	(6.72)	(8.25)
11	Paid-up equity share capital (Face value of share - Rs 10 each)	100.00	100.00	100.00	100.00	100.00	100.00
12	Other equity						1,848.82
	See accompanying notes to the unaudited consolidated financial results						



NURECA LIMITED

Correspondence Office : SCO 6-7-8, 1st Floor, Madhya Marg, Sector 9-D, Chandigarh 160009
Registered Office : 101 Office Number, Udyog Bhavan, 1st Floor, Sonawala Lane, Goregaon East,
Mumbai City Maharashtra - 400063

Phone No. +91-172-5292900 CIN L24304MH2016PLC320868

NURECA LIMITED

Office Number 101, 1st Floor Udyog Bhavan Sonawala Lane, Goregaon (East), Mumbai - 400063, Maharashtra, India
 Tel: +91 -172-5292900, E-mail: cs@nureca.com, Website: www.nureca.com
 Corporate Identification Number: L24304MH2016PLC320868

Notes to the unaudited consolidated financial results:

- The above unaudited consolidated financial results for the quarter and nine months ended 31 December 2023 as reviewed by the Audit Committee, have been approved at the meeting of the Board of Directors held on 07 February 2024. The limited review report of the Statutory Auditors is being filed with the BSE Limited and National Stock Exchange of India Limited. For more details, visit the investor relation section of our website www.nureca.com and financials results at corporate section at www.bseindia.com and www.nseindia.com.
- The business of the Group falls within single line of business i.e. business of home healthcare and wellness products.
- In respect of one of its subsidiary, "cost of materials consumed" and "changes in inventories" was inadvertently classified as "Purchase of stock in trade" in the quarters and periods ended 30 June 2022, 30 September 2022, 31 December 2022.

This classification has now been rectified and the financial information has been restated for quarter ended 31 December 2022 and nine months ended 31 December 2022 in accordance with Ind AS 8 "Accounting Policies, Changes in Accounting Estimates and Errors" in the consolidated financial results for the quarter ended 31 December 2023 and year to date results for the period from 1 April 2023 to 31 December 2023. The following table summarises the impact on the Consolidated financial results

Particulars	For the quarter ended 31 December 2022		
	As previously reported	Adjustment	Restated
Cost of material consumed	-	20.50	20.50
Purchase of stock in trade	104.11	(20.42)	83.69
Changes in inventories	63.02	(0.08)	62.94
Particulars	For the 9 months ended 31 December 2022		
	As previously reported	Adjustment	Restated
Cost of material consumed	-	27.96	27.96
Purchase of stock in trade	370.30	(38.81)	331.49
Changes in inventories	241.80	10.85	252.65

There is no impact of the restatement on the total expenditure, profit before tax / (loss), profit after tax / (loss) for the period and consequently on the earning per share (EPS).

For and on behalf of Board of Directors of Nureca Limited

Saurabh Goyal
 (Managing Director)
 DIN : 00136037

Place: Chandigarh
 Date: 07.02.2024

NURECA LIMITED

Correspondence Office : SCO 6-7-8, 1st Floor, Madhya Marg, Sector 9-D, Chandigarh 160009
 Registered Office : 101 Office Number, Udyog Bhavan, 1st Floor, Sonawala Lane, Goregaon East,
 Mumbai City Maharashtra - 400063

Phone No. +91-172-5292900 CIN L24304MH2016PLC320868

Limited Review Report on unaudited consolidated financial results of Nureca Limited for the quarter ended 31 December 2023 and year to date results from 01 April 2023 to 31 December 2023 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Nureca Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Nureca Limited (hereinafter referred to as "the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 31 December 2023 and year to date results for the period from 01 April 2023 to 31 December 2023 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.
4. The Statement includes the results of the following entities:
 - a. Nureca Limited - Parent Company (incorporated in India)
 - b. Nurca INC - Subsidiary Company (incorporated in U.S.A.)
 - c. Nureca Healthcare Private Limited - Subsidiary Company (incorporated in India)
 - d. Nureca Technologies Private Limited - Subsidiary Company (incorporated in India)
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review report of the other auditor referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We draw attention to Note 3 to the Statement, which more fully explains that in respect of one subsidiary, "cost of materials consumed" and "changes in inventories" was inadvertently classified as "Purchase of stock in trade" in the quarters and periods ended 30 June 2022, 30 September 2022, 31 December 2022. This classification has now been rectified and the figures presented for the

AG

Registered Office:

Limited Review Report (Continued)

Nureca Limited

corresponding quarter and nine month ended 31 December 2022 have been restated in accordance with the requirements of "Ind AS 8 : Accounting Policies, Changes in Accounting Estimates and Errors".

Our conclusion is not modified in respect of this matter.

7. We did not review the interim financial information of one Subsidiary included in the Statement, whose interim financial information reflects total revenues (before consolidation adjustments) of Rs. 54.31 millions and Rs. 114.25 millions, total net profit after tax (before consolidation adjustments) of Rs. 2.72 millions and Rs. 7.00 millions and total comprehensive income (before consolidation adjustments) of Rs. 2.72 and Rs. 7.00 millions, for the quarter ended 31 December 2023 and for the period from 01 April 2023 to 31 December 2023 respectively, as considered in the Statement. This interim financial information has been reviewed by other auditor whose report has been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter.

8. The Statement includes the interim financial information of two Subsidiaries which have not been reviewed, whose interim financial information reflect total revenues (before consolidation adjustments) of Rs. Nil and Rs. Nil, total net (loss) after tax (before consolidation adjustments) of Rs. 0.71 millions and Rs. 0.84 millions and total comprehensive loss (before consolidation adjustments) of Rs. 0.71 millions and Rs. 0.84 millions, for the quarter ended 31 December 2023 and for the period from 01 April 2023 to 31 December 2023 respectively, as considered in the Statement. According to the information and explanations given to us by the Parent's management, these interim financial information are not material to the Group.

Our conclusion is not modified in respect of this matter.

For B S R & Co. LLP

Chartered Accountants

Firm's Registration No.:101248W/W-100022



Ankush Goel

Partner

Membership No.: 505121

UDIN:24505121BKGXCX7104

New Delhi

07 February 2024